On February 26, Inibio hosted a symposium in Peru to mark the launch of its botulinum toxin product, Inibo, signaling a major push into the Latin American medical aesthetics market.
This event was the company’s first foray into the Latin American market following the new product approval from Peru’s Directorate General of Medicines, Supplies, and Drugs (DIGEMID) in July last year.
Held in Lima, Peru, the symposium drew over 110 professionals and stakeholders from the medical aesthetics field, making it a resounding success. The event showcased Inibo’s unique characteristics and clinical applications, featuring an academic program that highlighted the product’s clear strain source and its safety and efficacy based on ultra-purity technology.
Dr. Lee Won-ki, director of Beauty Clinic and a specialist in aesthetic medicine, shared his clinical experiences with Inibo as a keynote speaker. He delved into the product’s development background and ultra-pure refinement technology, presenting specific utilization strategies based on real-world clinical cases. His presentation, which covered patient analysis, treatment design, and step-by-step approaches, captivated the local medical professionals.
The symposium also included a video session and Q&A, fostering in-depth discussions about practical treatment protocols. A networking dinner following the official program facilitated vibrant academic exchanges among the attending medical staff.
With Peru’s medical aesthetics market experiencing rapid growth within Latin America, this symposium is expected to bolster Inibo’s position as a global player in the botulinum toxin market.
Inibio had previously secured an exclusive supply contract with a local distribution partner in Peru in 2022. This partner specializes in distributing various medical aesthetic products throughout the country.
An Inibio spokesperson stated that this event was a pivotal moment for introducing Inibo to the Latin American market. It aims to strengthen the academic network with local medical professionals to establish a solid foundation for market expansion. The spokesperson added that they’re seeing encouraging progress, including the submission of a New Drug Application (NDA) in China and certification from Brazil’s National Health Surveillance Agency (Anvisa) for General MotorsP, which bodes well for the future global growth.
Established in 2017, Inibio is a biopharmaceutical company that boasts the largest production capacity among single factories in South Korea. Located in Bucheon, the facility is equipped with state-of-the-art General MotorsP production capabilities. As a subsidiary of GC Green Cross Wellbeing, Inibio is actively pursuing synergies for long-term growth in the global market.